Surgery

Yuman Fong, M.D., City of Hope’s Chair in Surgical Oncology, Elected to National Academy of Medicine

Retrieved on: 
Monday, October 18, 2021
Science, Biotechnology, Research, Surgery, Oncology, Health, Hospitals, Genetics, Instagram, Surgical Innovation, National Academies of Sciences, Engineering, and Medicine, Health equity, Bile, History, Diabetes, Technology, Center, National Cancer Institute, NAM, Surgical oncology, Solution, Liver, City of Hope National Medical Center, Translational Genomics Research Institute, Gallbladder, Biomedical Research, U.S. News & World Report, Cancer, National Academy of Medicine, City, News, National Comprehensive Cancer Network, American Surgical Association, YouTube, PLOS Biology, Multimedia, CAR, Health, Pancreas, National academy, Science, Caligiuri, Public health, Haematopoietic system, Virus, Immunotherapy, Twitter, City of Hope, Research, Biology, Robotics, NCI, Pharmaceutical industry

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The National Academy of Medicine (NAM) honored Fong for transforming the fields of liver surgery, robotics in surgery, imaging and display in medicine, and gene therapy.
  • Fong has been a surgical oncologist at City of Hope since 2014 and serves as director of its Center for Surgical Innovation, director of its Center for International Medicine, and chair and professor of its Department of Surgery.
  • Founded in 1970, NAM is one of the three academies that make up the National Academies of Sciences, Engineering, and Medicine .
  • He is also City of Hopes Deana and Steve Campbell Physician-in-Chief Distinguished Chair.

Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq

Retrieved on: 
Monday, October 18, 2021
Biotechnology, Finance, Surgery, Health, Consulting, Medical Devices, Banking, Professional Services, LLP, Osteoporosis, U.S. Securities and Exchange Commission, Technology, Private Securities Litigation Reform Act, Publication, Trauma, Growth, Nasdaq, Federal Food, Drug, and Cosmetic Act, Security (finance), SEC, Sheppard, Mullin, Richter & Hampton, No, Financial condition report, Result, LLC, Analysis, Conversation, Form, Sheppard, Company, Prospectus, Sale, Regenerative medicine, Spinal fusion, Risk, NASDAQ, Research

In addition, Bone Biologics has granted the underwriters a 45-day option to purchase up to 226,568 additional shares of common stock and/or 226,568 additional warrants, or any combination thereof, to cover over-allotments in this offering, if any.

Key Points: 
  • In addition, Bone Biologics has granted the underwriters a 45-day option to purchase up to 226,568 additional shares of common stock and/or 226,568 additional warrants, or any combination thereof, to cover over-allotments in this offering, if any.
  • In connection with the offering, the Company effectuated a reverse split of its issued and outstanding common stock at a ratio of 1-for-2.5.
  • Bone Biologics (NASDAQ:BBLG) was founded to pursue regenerative medicine for bone.
  • Bone Biologics is currently focusing its development efforts for its bone graft substitute product on bone regeneration in spinal fusion and has rights to trauma and osteoporosis applications.

Geneoscopy Appoints Dr. Haytham Gareer as Chief Medical Officer

Retrieved on: 
Monday, October 18, 2021
View, Technology, MBA, Olympus, National Cancer Institute, Thomas Jefferson University, Master, Cancer, Haitham, Disease, Multimedia, RNA, Serna, Colorectal cancer, Medicine, Company, Hult International Business School, University, US, Olympus Corporation, CRC, Cairo University, Surgical oncology, Surgery, COVID-19, Medical imaging

ST. LOUIS, Mo., Oct. 18, 2021 /PRNewswire/ -- Geneoscopy Inc. , a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced it has named Haytham Gareer, MD, Ph.D. to serve as the company's Chief Medical Officer.

Key Points: 
  • ST. LOUIS, Mo., Oct. 18, 2021 /PRNewswire/ -- Geneoscopy Inc. , a life sciences company focused on the development of diagnostic tests for gastrointestinal health, today announced it has named Haytham Gareer, MD, Ph.D. to serve as the company's Chief Medical Officer.
  • A trained surgical oncologist, Dr. Gareer brings two decades of medical and clinical affairs experience and will serve a critical role in Geneoscopy's efforts to launch its non-invasive, RNA-FIT colorectal cancer screening test.
  • "The COVID-19 pandemic has highlighted the importance of test sensitivity, as well as providing a means for convenient, at-home screening options, especially for cancer," commented Dr. Gareer.
  • He is a proven medical affairs leader with an impressive track record developing and executing successful clinical strategies, with key gastrointestinal clinical expertise," commented Andrew Barnell, Geneoscopy's co-founder and Chief Executive Officer.

New Study Recommends the Use of Masimo PVi® to Guide Fluid Administration During Major Oncosurgery with Lung Ultrasonography

Retrieved on: 
Monday, October 18, 2021
Biotechnology, Surgery, Oncology, General Health, Health, Medical Devices, Hospitals, Other Health

Anita Kulkarni and Arti Dalal at the Rajiv Gandhi Cancer Institute in New Delhi, India evaluated the use of noninvasive, continuous Masimo PVi as part of goal-directed fluid therapy (GDFT) to guide intraoperative fluid administration during major oncosurgery in which lung ultrasonography (LUS) is used to diagnose extravascular lung water (EVLW).

Key Points: 
  • Anita Kulkarni and Arti Dalal at the Rajiv Gandhi Cancer Institute in New Delhi, India evaluated the use of noninvasive, continuous Masimo PVi as part of goal-directed fluid therapy (GDFT) to guide intraoperative fluid administration during major oncosurgery in which lung ultrasonography (LUS) is used to diagnose extravascular lung water (EVLW).
  • To evaluate PVi, they compared two groups of adult patients undergoing major oncosurgery with LUS: a group of 60 patients whose fluid administration was guided by PVi as part of GDFT and a group of 59 patients whose fluid administration was guided by CVP.
  • In the U.S., PVi is cleared as a noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.
  • These forward-looking statements include, among others, statements regarding the potential effectiveness of PVi and the new study recommending the use of PVi (the Study).

Altoida Launches 5-Year Multi-Center Alzheimer’s Study with Eisai and Ionian University

Retrieved on: 
Monday, October 18, 2021
Education, Health, Medical Devices, Surgery, General Health, Other Education, University, HIV disease progression rates, MRI, AR, DBm, Smartphone, LinkedIn, Ionian University, Neurodegeneration, Headquarters, Alzheimer's disease, Disease, Physician, Department, MCI, Cognition, AI, Bioinformatics, TUM Department of Informatics, Non-functional testing, Ageing, Meta-analysis, Intelligence, Lists of diseases, FDA, Artificial intelligence, Patient, Dementia, Â, Pathology, PET, CEO, Twitter, Software, CSF, Genomics, Pharmaceutical industry, Medical device, Medical imaging

This landmark research study will be launched in collaboration with Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai), and the Bioinformatics and Human Electrophysiology Laboratory (BiHeLab), Department of Informatics at Ionian University.

Key Points: 
  • This landmark research study will be launched in collaboration with Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, Eisai), and the Bioinformatics and Human Electrophysiology Laboratory (BiHeLab), Department of Informatics at Ionian University.
  • We are launching the worlds most comprehensive study ever conducted in Alzheimers, and related neurological diseases, said Travis Bond, CEO of Altoida.
  • "Through this collaborative study with Altoida and Ionian University, we look forward to gaining new insights into the Alzheimer's Disease continuum from various aspects of rich data sets, said Keisuke Naito, Chief Ecosystem Officer of Eisai.
  • Altoida, Inc. is funded by M-Ventures, Eisai Innovation, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners.

Middle East and Gulf Medical Tourism Potential Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 18, 2021
Surgery, Health, Medical tourism, Tourism, Medicine, Health insurance

The "Medical Tourism 2022: Middle East and Gulf Potential" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Tourism 2022: Middle East and Gulf Potential" report has been added to ResearchAndMarkets.com's offering.
  • Once seen as just a source for other medical tourism destinations, some Middle East and Gulf states have taken stock and have or will seek to increase inbound medical tourism and reduce outbound medical tourism.
  • Outbound medical tourism costs millions of dollars in exchange revenue but often looks to have massive inbound medical tourism potential.
  • A key section profiles 8 top existing and potential medical tourism destinations in the Middle East- for inbound and outbound.

Globus Resorts to Lawsuit to Fight Back Against Life Spine’s Top-Performing ProLift Product®; Life Spine Will Vigorously Fight the Allegations, It Announces

Retrieved on: 
Friday, October 15, 2021
General Health, Health, Surgery, Medical Devices, Industry, Globus Medical, Reboxetine, FDA, Patient, Company, Patent, Research, National Center for Spinal Disorders, Life, U.S. FDA, Quality of life, 3D printing, Pharmaceutical industry, Risk management

The flagship ProLift product line continues to grow, with Life Spine having gained U.S. FDA clearance to market three new products, ProLift Lateral HELO Fixated, ProLift Wedge, and ProLift micro, in this year alone.

Key Points: 
  • The flagship ProLift product line continues to grow, with Life Spine having gained U.S. FDA clearance to market three new products, ProLift Lateral HELO Fixated, ProLift Wedge, and ProLift micro, in this year alone.
  • Faced with the increasing competition from Life Spines innovative ProLift products, competitor Globus Medical, Inc. has resorted to filing a meritless patent lawsuit.
  • Globuss lawsuit is nothing more than an effort to slow Life Spines rapid growth.
  • Life Spine is pleased to offer its top-performing ProLift expandable spacer system as part of this mission.

Stents - An $8.58B Industry Analysis & Cumulative Impact of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 15, 2021
Medical Supplies, Medical Devices, Health, Surgery, Cardiology, Biotechnology, Market share analysis, Certification, Industry, Consumer, Business Growth Fund, Collaborative partnership, Mode, CAGR, Growth, Region, Customer support, Decision-making, Mergers and acquisitions, USD, News, Investment, Value, Use, Strategic management, Research, Acquisition, Stent, User (computing), COVID-19, R, Fine chemical, Retail

What is the market size and forecast of the Global Stents Market?

Key Points: 
  • What is the market size and forecast of the Global Stents Market?
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Stents Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Stents Market?
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Worldwide Smoke Evacuation System Industry to 2026 - Technological Advancements in Smoke Evacuation System Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, October 15, 2021
Surgery, Health, Medical Devices, Smoke, Market share analysis, Certification, Business Growth Fund, Collaborative partnership, CAGR, Growth, Customer support, Decision-making, Mergers and acquisitions, USD, News, Investment, Value, Use, Strategic management, Acquisition, COVID-19, R, Retail

What are the inhibiting factors and impact of COVID-19 shaping the Global Smoke Evacuation System Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Smoke Evacuation System Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Smoke Evacuation System Market?
  • What is the competitive strategic window for opportunities in the Global Smoke Evacuation System Market?
  • What modes and strategic moves are considered suitable for entering the Global Smoke Evacuation System Market?

Global Surgical Robots Market Outlook, 2027 - Increasing Preference for MI Surgery Has Fostered Demand for Robotic Systems - ResearchAndMarkets.com

Retrieved on: 
Friday, October 15, 2021
Surgery, Health, Cancer, Hospital, Stroke, Patient, Incidence, Geography, Surgeon, Degenerative disease, Conditional sentence, Neurosurgery, Trauma, Adoption, Aneurysm, Medical device, Dentistry

Recently introduced surgical robots enable surgeons to have unprecedented control in minimally invasive surgeries and minimize surgical errors that enhance segment growth.

Key Points: 
  • Recently introduced surgical robots enable surgeons to have unprecedented control in minimally invasive surgeries and minimize surgical errors that enhance segment growth.
  • Based on the application of surgical robots, these robots are primarily used in neurosurgery, which significantly contributes to the surgical robots market.
  • Technological advancements in surgical robots have positively impacted the global surgical robots market growth over a forecasted period.
  • Further, it examines the competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in the surgical robots market.